A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

@article{Zuardi2012ACR,
  title={A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.},
  author={A. Zuardi and J. Crippa and J. Hallak and S. Bhattacharyya and Z. Atakan and R. Mart{\'i}n-Santos and P. McGuire and F. Guimar{\~a}es},
  journal={Current pharmaceutical design},
  year={2012},
  volume={18 32},
  pages={
          5131-40
        }
}
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal… Expand
A systematic review of the antipsychotic properties of cannabidiol in humans
TLDR
Results show the ability of CBD to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration, and the potential of CBD as an effective, safe and well-tolerated antipsychotic compound, although large randomised clinical trials will be needed before this novel therapy can be introduced into clinical practice. Expand
The development of Cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (?9-THC/THC). In the last 30 years, CBD hasExpand
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
TLDR
CBD is an useful and promising molecule that may help patients with a number of clinical conditions and should bring important answers in the near future and support the translation of research findings to clinical settings. Expand
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
TLDR
Recent in vivo studies indicating that the mechanisms responsible for CBD therapeutic potential are not unitary but rather depend on the behavioural response being measured suggest activation of TRPV1 channels may help to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD. Expand
Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders
Abstract Despite schizophrenia being among the most debilitating and costly adult psychiatric disorders, current antipsychotic therapies have limited efficacy and are associated with a high incidenceExpand
Could cannabidiol be used as an alternative to antipsychotics?
  • M. Fakhoury
  • Psychology, Medicine
  • Journal of psychiatric research
  • 2016
TLDR
CBD, a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs. Expand
Cannabidiol as a potential treatment for psychosis
TLDR
CBD, a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action and the prospects of CBD as a possible novel treatment for psychotic disorders are set out. Expand
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
  • E. Perucca
  • Medicine
  • Journal of epilepsy research
  • 2017
TLDR
There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes, for the first time, according to currently available information. Expand
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
TLDR
This study investigated the effects of peripubertal treatment with CBD in behaviors that mimic the positive and negative symptoms of schizophrenia in animals and found CBD is a promising candidate since as far as known it does not promote side effects and it is well tolerated. Expand
Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
TLDR
Results from these studies are promising and suggest that CBD may have a role in the development of new therapeutic strategies in mental diseases, and they justify an in-depth commitment in this field. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
TLDR
The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD and confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Expand
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
  • A. Zuardi
  • Psychology, Medicine
  • Revista brasileira de psiquiatria
  • 2008
TLDR
In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of great therapeutic interest, but still waiting to be confirmed by clinical trials. Expand
[Therapeutical use of the cannabinoids in psychiatry].
TLDR
Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions, and Delta(9)-tetrahydrocannabinol and its analogues were shown to have anxIOlytic effects in the treatment of cannabis dependence. Expand
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
TLDR
Cannabidiol and Delta(9)-tetrahydrocannabivarin, a novel CB(1) antagonist which exerts potentially useful actions in the treatment of epilepsy and obesity are given special emphasis. Expand
Safety and side effects of cannabidiol, a Cannabis sativa constituent.
TLDR
In vivo and in vitro reports of CBD administration across a wide range of concentrations suggest controlled CBD may be safe in humans and animals, but further studies are needed to clarify reported in vitro and in vivo side effects. Expand
Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
TLDR
In conclusion, cannabidiol showed both propsychotic activity and partial antipsychotic activity in an MK-801-induced model of aspects of schizophrenia, and showed potential towards inhibiting MK-802-induced social withdrawal. Expand
The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
TLDR
It is confirmed that THC can induce a transient, acute psychotic reaction in psychiatrically well individuals and the extent of the psychotic reaction was not related to the degree of anxiety or cognitive impairment. Expand
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days. Expand
Effects of cannabidiol in animal models predictive of antipsychotic activity
TLDR
CBD has a pharmacological profile compatible with that of an “atypical” antipsychotic agent, though the mechanism of action is uncertain and may not be identical to that of the dopamine antagonists. Expand
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
TLDR
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia. Expand
...
1
2
3
4
5
...